Cagrilintide and Amylin Analogue Research: The Complete Guide (incl. CagriSema)

Cagrilintide is a long-acting, acylated analogue of human amylin that acts as a non-selective agonist at the amylin and calcitonin receptors. This cagrilintide research peptide guide explains amylin biology, how the amylin receptor is assembled from a calcitonin receptor plus a RAMP subunit, what makes cagrilintide different from native amylin, and why the compound is studied alongside GLP-1 analogues in the combination known in the literature as CagriSema. Written for laboratory researchers handling lyophilised material under research-use-only terms.

Updated 10 September 2026~14 min readReviewed by the GenoPept technical team

What is amylin and why does it matter?

Amylin, also called islet amyloid polypeptide or IAPP, is a 37-amino-acid peptide hormone stored in the same beta-cell secretory granules as insulin and released with it after a meal. It carries an intramolecular disulfide bridge near the N-terminus and a C-terminal amide, both of which are required for activity.

Its published physiological role is to act as a satiation and nutrient-flux signal. Reviews of amylin pharmacology describe receptor activation as slowing gastric emptying, inhibiting glucagon secretion and reducing food intake — a set of effects that complements insulin’s actions on glucose disposal rather than duplicating them.

The reason amylin became a drug-design target rather than simply a physiological curiosity is that native human amylin is difficult material. It aggregates readily into amyloid fibrils, which is both a formulation problem and the basis of its association with islet pathology in type 2 diabetes. Every therapeutic amylin analogue is, at heart, an attempt to keep the pharmacology while removing the aggregation.

The amylin receptor: CTR plus a RAMP

The amylin receptor is not a single gene product. It is a heterodimer: the calcitonin receptor (CTR), a class B G-protein-coupled receptor, complexed with one of three receptor activity-modifying proteins. CTR with RAMP1 gives AMY₁, with RAMP2 gives AMY₂, and with RAMP3 gives AMY₃.

This architecture has a direct practical consequence for assay design. The pharmacology you measure depends on which RAMP is co-expressed in your cell system, and on the ratio of RAMP to CTR. A “CTR-transfected” line with no RAMP present is a calcitonin receptor assay, not an amylin receptor assay, and will give different potency values for the same ligand.

What is cagrilintide?

Cagrilintide is a long-acting acylated amylin analogue developed under the codes AM833 and NN0174-0833. It is an agonist at the amylin receptors and at the calcitonin receptor, with reported binding affinities in the low sub-nanomolar range at both — approximately 170 pM at the human amylin 3 receptor and approximately 223 pM at the human calcitonin receptor in supplier characterisation data.

Structural work published in Nature Communications in 2025 resolved cagrilintide bound to AMY₁, AMY₂, AMY₃ and CTR by cryo-electron microscopy. That study reported cagrilintide adopts an amylin-like binding mode and stabilises a “bypass” conformation of the peptide’s mid-region across all four receptor complexes, unlike rat amylin which samples both bypass and calcitonin-like conformations.

That conformational selectivity is the interesting part for anyone reading the pharmacology. Cagrilintide is not more selective than amylin between receptors; it is more selective between conformations at the same receptors, and the published interpretation is that this consistency contributes to its potency profile.

Cagrilintide structure: six changes from human amylin

Cagrilintide retains the human amylin backbone length, the N-terminal disulfide loop and the C-terminal amide, but changes six positions and adds a lipid chain. Reading the two sequences side by side is the fastest way to understand the design.

Human amylin (IAPP):

KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY

Cagrilintide (modified residues highlighted; the N-terminal lysine carries the acyl chain):

KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP

What each change does

1. N14E and V17R. This pair introduces a negative and a positive charge that form an intramolecular salt bridge. Structural work identifies these substitutions as the main anti-amyloid feature — they disrupt the beta-sheet stacking that drives native amylin into fibrils.
2. A25P, S28P, S29P. Three proline substitutions in the aggregation-prone mid-to-C-terminal region. Proline cannot participate in a beta-sheet hydrogen-bonding pattern, so these positions break fibril formation. The same three substitutions define the earlier amylin analogue pramlintide.
3. Y37P. Replacing the C-terminal tyrosine with proline changes how the peptide contacts the RAMP subunit. Published structural work reports this reduces direct RAMP interaction relative to amylin while preserving potency through alternative contacts, and it makes the C-terminus resemble a calcitonin-family arrangement.
4. C20 diacid acylation via γGlu on Lys1. An eicosanedioic acid chain attached through a γ-glutamate spacer at the N-terminal lysine gives reversible albumin binding, which is what turns a short-acting hormone into a once-weekly research compound.
5. Retained Cys2–Cys7 disulfide. The N-terminal loop is preserved because it is required for receptor activation; this is why reducing agents must be kept away from cagrilintide solutions.
6. Retained C-terminal amide. As in native amylin, the C-terminus is amidated rather than a free acid.

Molecular specifications

Cagrilintide’s identity data should appear on any certificate of analysis. The disulfide bond means an MS result must be interpreted against the oxidised (cyclised) mass, which is two hydrogen atoms lighter than the linear chain.

Amylin analogues compared

Three molecules define the amylin analogue landscape: native human amylin, the first-generation analogue pramlintide, and cagrilintide. They differ mainly in how far the anti-aggregation engineering was taken and whether duration of action was addressed at all.

Cagrilintide with semaglutide: the CagriSema research

The most-studied application of cagrilintide is co-administration with the GLP-1 analogue semaglutide, referred to in the literature as CagriSema. The rationale is that amylin and GLP-1 act through different receptors and different circuits, so the two signals should be additive rather than redundant.

The published programme runs from a phase 1b co-administration study through phase 2 in type 2 diabetes to a large phase 3 trial. In the phase 3 REDEFINE 1 trial, reported in the New England Journal of Medicine in 2025, 3,417 adults with obesity or overweight plus at least one comorbidity were randomised for 68 weeks; the combination arm showed a mean body-weight reduction of 22.7% versus 2.3% with placebo. These are clinical trial results for an investigational pharmaceutical combination and are described here purely as research context.

What this means for a laboratory buyer

Two practical points follow. First, a blend vial containing both compounds cannot be separated after reconstitution, so if your experiment needs to vary the ratio you need the two single compounds rather than a fixed-ratio blend. Second, a blend’s certificate of analysis should report both components separately — a single purity figure for a two-peptide vial tells you very little.

Amylin blends and combinations in the store

GenoPept stocks cagrilintide as a single compound and in two fixed-ratio blends. All are lyophilised research material with per-batch certificates of analysis.

Reconstitution and solution concentrations

Cagrilintide is supplied as a lyophilised cake and reconstituted with sterile or bacteriostatic water. The figures below are a concentration reference for solution preparation in a laboratory, not a dosing schedule for any organism.

1. Bring to room temperature. Open the vial only once it has equilibrated, to avoid condensation onto the lyophilised cake.
2. Sanitise both stoppers. Wipe with 70% isopropyl alcohol and allow to dry before piercing.
3. Add diluent down the wall. Direct the stream onto the glass, not the cake. A disulfide-containing peptide is particularly sensitive to shear-induced unfolding.
4. Dissolve passively. Swirl gently or stand the vial. Never vortex or shake.
5. Check clarity. Any haze, wisps or particulates indicate aggregation and the solution should not be used for quantitative work.
6. Label and refrigerate. Record compound, batch, concentration and date, then store at 2–8 °C away from light.

Molarity assumes the label mass is free peptide at MW 4,409 Da. Correct using the net peptide content figure from the certificate of analysis where exact molar concentration matters. The full method, including how to handle multi-peptide vials, is in our reconstitution guide.

Storage, stability and quality verification

Two features of cagrilintide’s chemistry drive its handling requirements: the disulfide loop and the fatty-acid chain. The disulfide is vulnerable to reduction and to disulfide scrambling at alkaline pH; the acyl chain promotes surface adsorption and, at high concentration, self-association.

For quality verification, reverse-phase HPLC gives chromatographic purity and mass spectrometry confirms identity against the calculated oxidised mass. For a disulfide-containing peptide it is worth confirming that the observed mass corresponds to the cyclised form; a mass two units higher suggests the reduced, linear peptide, which is a different molecule pharmacologically. Both measurements appear on the batch certificates at our COA page, and are explained in detail in our peptide purity testing guide.